NAD+ · Research brief
What Is NAD+ and Why Is It Important? (NAD+ vs NADH)
Short answer
Every cell you have runs on a molecule it cannot store, cannot import intact, and has to rebuild on a clock measured in hours. That molecule spends its whole working life flipping between two forms, and that flip is exactly where most explanations fall apart.
Key takeaways
- NAD+ (nicotinamide adenine dinucleotide) is built from one adenine, one nicotinamide, two ribose sugars and two phosphate groups, with a molecular weight near 663 g/mol.
- NAD+ is reduced to NADH when it accepts a hydride ion; NADH is oxidised back to NAD+ at Complex I of the electron transport chain, yielding roughly 2.5 ATP by standard estimates.
- NADH is not a different molecule from NAD+ and is not in competition with it, so asking which is better is asking the wrong question; the NAD+/NADH ratio is what the literature tracks.
- All three B3 vitamers feed NAD+ synthesis through distinct enzymes: NAPRT for nicotinic acid, NAMPT for nicotinamide, NRK1 and NRK2 for nicotinamide riboside.
- Sirtuins, PARPs and CD38 consume NAD+ outright rather than recycling it, which is why the salvage pathway runs continuously.
- Extracellular NAD+ is broken down by CD38 and CD73 into smaller precursors before cells take it up, so intact delivery is not how the molecule enters.
- Research-grade NAD+ supplied by Real Peptides ships with a certificate of analysis and is intended for laboratory research only.
Every cell you have runs on a molecule it cannot store, cannot import intact, and has to rebuild on a clock measured in hours. That molecule spends its whole working life flipping between two forms, and that flip is exactly where most explanations fall apart.
We supply NAD+ as a research compound, and the technical questions labs send us are almost never about benefits. They're about the redox pair. So that's where anyone searching 'what is NAD+ and why is it important' should start too.
What is NAD+ and why is it important?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell that shuttles electrons between metabolic reactions and acts as a consumable substrate for repair enzymes. It matters because no cell makes ATP without continuously cycling NAD+ into NADH and back, a turnover research suggests happens within hours.
The common oversimplification is that NAD+ is a form of energy. It isn't. It's a carrier and a substrate, and NADH isn't a competing molecule but the same molecule holding cargo. This piece covers the components of NAD+, the direction of the redox reaction, whether vitamin B3 raises NAD+ levels, and what the published research does and doesn't demonstrate.
The components of NAD+, piece by piece
NAD+ is a dinucleotide, meaning two nucleotides joined tail to tail through a pair of bridging phosphate groups. One half is adenosine monophosphate (AMP), carrying the same adenine base and ribose sugar found in ATP and DNA. The other half is nicotinamide mononucleotide (NMN), built from the vitamin B3 derivative nicotinamide attached to its own ribose and phosphate.
So the full parts list is short: one adenine, one nicotinamide, two ribose sugars, two phosphates. Molecular weight lands around 663 g/mol for the free acid, which is large for something that has to move through cellular compartments constantly.
The nicotinamide ring does the actual chemistry. Its C4 position accepts a hydride ion, and the positive charge sits on the ring nitrogen, which is where the plus sign comes from. The plus does not mean more, better, or upgraded. It's a charge notation, nothing else.
One close relative deserves a mention because it gets conflated constantly. NAD kinase phosphorylates the 2-hydroxyl on the adenosine ribose to make NADP+, and the NADPH pool that results serves reductive biosynthesis and antioxidant recycling, including the glutathione reductase reaction that regenerates reduced glutathione. Same backbone, separate pool, different job.
In our experience fielding technical questions from research buyers, that plus sign causes more confusion than any other feature of the molecule.
NAD+ vs NADH: which form is which, and which one matters
NAD+ is reduced to NADH, not the reverse. If you've read that NADH is reduced to NAD+, that's the reaction described backwards: NADH is oxidized back to NAD+ when it hands its electrons off.
Dehydrogenase enzymes strip a hydride, one proton plus two electrons, from a substrate and load it onto NAD+. Glyceraldehyde-3-phosphate dehydrogenase does this in glycolysis. Isocitrate dehydrogenase and malate dehydrogenase do it in the TCA cycle. Beta-oxidation of fatty acids does it too. NADH then carries that cargo to Complex I of the electron transport chain (NADH:ubiquinone oxidoreductase), where the electrons flow downhill, protons get pumped, and ATP synthase does the rest. Standard P/O estimates put the yield at roughly 2.5 ATP per NADH.
The regeneration step is the one people skip. Without NAD+ coming back, glycolysis stalls at the GAPDH step almost immediately, which is precisely why lactate dehydrogenase exists: converting pyruvate to lactate regenerates NAD+ when oxygen is scarce.
Is NADH the same as NAD+? Same molecular scaffold, two oxidation states, opposite roles. Which is better, NAD+ or NADH? That's a category error. What the literature actually tracks is the ratio, and it's compartmentalised: classic metabolite-indicator estimates put the free cytosolic NAD+/NADH ratio in the hundreds to one, while the mitochondrial matrix pool sits dramatically lower. We see that distinction missed in half the assay questions we get.
Where NAD+ goes: consumption, precursors, and whether B3 raises it
Beyond redox cycling, NAD+ is destroyed and rebuilt constantly because an entire enzyme family consumes it as a substrate rather than recycling it. Sirtuins (SIRT1 through SIRT7, NAD+-dependent deacylases), PARPs (poly(ADP-ribose) polymerases, which respond to DNA damage), and CD38 (a cell-surface NADase) all cleave the glycosidic bond between nicotinamide and ribose, releasing free nicotinamide.
That's why the salvage pathway is the dominant route. NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme converting nicotinamide back to NMN, and the NMNAT enzymes adenylylate NMN into finished NAD+.
Does B3 increase NAD+? Yes, in the sense that every B3 vitamer feeds a biosynthetic route: nicotinic acid enters through the Preiss-Handler pathway via NAPRT, nicotinamide enters through salvage via NAMPT, and nicotinamide riboside is phosphorylated by NRK1 and NRK2. Tryptophan supports de novo synthesis through the kynurenine pathway, inefficiently. Human work published in Nature Communications by Trammell and colleagues in 2016 reported that oral nicotinamide riboside is bioavailable and raises blood NAD+, and a 2018 Nature Communications trial by Martens and colleagues reported elevated NAD+ in peripheral blood mononuclear cells with chronic NR intake.
Here's the part most summaries omit. Intact NAD+ is a large, negatively charged dinucleotide and doesn't simply cross the plasma membrane. Research indicates ectoenzymes including CD38 and CD73 dismantle extracellular NAD+ into nicotinamide riboside and nicotinamide before transport, meaning cells take delivery as precursors regardless of what the starting material was. Everything described here is laboratory biochemistry; research-grade NAD+ is not an FDA-approved drug and isn't for human or veterinary consumption.
Quick comparison: the NAD family and its precursors
The table below separates the two oxidation states, the phosphorylated cousin, and the three B3 vitamers that feed the pool. It exists because these seven items get treated as interchangeable in most consumer-facing writing, and they aren't.
| Molecule or precursor | What it is chemically | Main job in the cell | Bottom line |
|---|---|---|---|
| NAD+ (oxidised) | Dinucleotide of AMP and NMN; positive charge sits on the nicotinamide ring nitrogen | Accepts a hydride in glycolysis, beta-oxidation and the TCA cycle; also a consumed substrate for sirtuins, PARPs and CD38 | The limiting currency of the system, because it's both recycled as a carrier and permanently destroyed as a substrate |
| NADH (reduced) | The same molecule after accepting a hydride at the C4 position of the nicotinamide ring | Delivers electrons to Complex I of the electron transport chain, driving proton pumping and ATP synthesis | Not a rival to NAD+ and not a separate compound; it's the loaded state of one molecule |
| NADP+ / NADPH | NAD+ phosphorylated at the 2-hydroxyl of the adenosine ribose by NAD kinase | Reductive biosynthesis of fatty acids and sterols, plus regeneration of glutathione and thioredoxin systems | A separate pool with a separate job, so NADPH findings shouldn't be read as NAD+ findings |
| Nicotinic acid (niacin) | Pyridine-3-carboxylic acid, a B3 vitamer | Enters NAD+ synthesis through the Preiss-Handler pathway via NAPRT | Raises NAD+ through a real enzymatic route, though GPR109A-mediated flushing limits tolerability at higher intakes |
| Nicotinamide (niacinamide) | The amide form of B3 and the direct breakdown product of NAD+ consumption | Recycled through the salvage pathway by NAMPT, the rate-limiting enzyme | Feeds the dominant recycling route, but also acts as a sirtuin inhibitor at high concentrations in cell-free work |
| Nicotinamide riboside (NR) | Nicotinamide attached to a ribose, no phosphate | Phosphorylated by NRK1 and NRK2 into NMN, then converted to NAD+ | Carries the most developed human pharmacokinetic dataset of any precursor studied to date |
| NAD+ as a formulated product | The intact dinucleotide, around 663 g/mol and negatively charged | Degraded extracellularly by CD38 and CD73 before any cellular uptake occurs | Cells receive it as precursors, not as intact NAD+, which changes how results should be interpreted |
What If: common NAD+ research scenarios
What if a source says NADH is reduced to NAD+?
Treat that source as unreliable on redox chemistry generally. The reduction runs NAD+ to NADH, and the reverse direction is an oxidation. This reversal appears often enough in consumer health writing that it's a fast credibility filter, and it usually travels alongside the claim that NADH is a separate, superior compound.
What if a product claims it delivers NAD+ directly into cells?
Read that claim against the membrane transport literature before accepting it. The intact dinucleotide is large and charged, and ectoenzymes including CD38 and CD73 cleave extracellular NAD+ into nicotinamide riboside and nicotinamide before transporters move anything inward. A claim of direct intracellular delivery of intact NAD+ needs specific supporting data, not a mechanism diagram.
What if B3 from a normal diet already covers NAD+ synthesis?
Dietary B3 does supply the substrate, which is why frank deficiency (pellagra) is rare where food is fortified. The open research question isn't substrate availability at baseline, it's whether pushing precursor intake above adequacy meaningfully shifts tissue NAD+ and, separately, whether that shift changes any functional endpoint. Those are two different questions and the evidence quality differs sharply between them.
What if the research model involves live animals?
Route the work through an approved institutional animal care protocol first, and talk to your veterinarian before anything else. Rodent NAD+ literature is extensive, but species differences in NAMPT expression, CD38 activity and precursor handling mean mouse pharmacokinetics don't transfer cleanly to other species. A licensed veterinarian is the right party to review any in vivo plan. A supplier is not.
The unglamorous truth about NAD+ supplement research
Here's the honest answer: raising a biomarker and changing an outcome are not the same achievement, and the NAD+ field has done far more of the first than the second. Published human trials have repeatedly shown that oral precursors elevate measurable NAD+ in blood compartments, often within days. What remains thin is the functional endpoint data, because most trials have been small, short, and focused on safety and pharmacokinetics rather than hard outcomes. Anyone asking whether NAD+ supplements are worth it should know that the measurement moves reliably and the clinical picture is still being assembled.
Our NAD+ materials and their documentation sit in a few places on our site: the NAD+ research overview covers the biochemistry background, while NAD+ 100mg and the NAD+ liquid spray list specifications for laboratory work, every batch has third-party documentation on the certificates of analysis page, and the rest of the research compounds are catalogued in the full shop. All materials are sold strictly for laboratory research use and are not for human or veterinary consumption.
Strip away the marketing and 'what is NAD+ and why is it important' reduces to a cycle rather than a substance. The molecule isn't valuable because it's present, it's valuable because it keeps moving, accepting a hydride here and releasing it there thousands of times before an enzyme finally consumes it and the salvage pathway builds another. Anything that treats NAD+ as a quantity to be topped up, rather than a flux to be sustained, has already lost the biochemistry. That distinction is where the interesting research still lives.
References
Peer-reviewed sources on NAD+ indexed in PubMed, listed for research context. Real Peptides supplies NAD+ for laboratory research use only.
- NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 2026. PMID 41655607. doi:10.1016/j.arr.2026.103057
- NAD(+) restores proteostasis through splicing-dependent autophagy. Autophagy, 2026. PMID 41313318. doi:10.1080/15548627.2025.2596679
- Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. PMID 42033099. doi:10.1002/alz.71423
- NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations. JCI insight, 2026. PMID 41574612. doi:10.1172/jci.insight.181812
- NAD(+) depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. Journal of neuroinflammation, 2025. PMID 41299539. doi:10.1186/s12974-025-03638-6
- Lactate dehydrogenase A-coupled NAD(+) regeneration is critical for acute myeloid leukemia cell survival. Cancer & metabolism, 2025. PMID 40390151. doi:10.1186/s40170-025-00392-4
- FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NAD(+) replenishment as a redox-targeted antioxidant therapy. Redox report : communications in free radical research, 2025. PMID 41021886. doi:10.1080/13510002.2025.2565033
- NAD+ prevents chronic kidney disease by activating renal tubular metabolism. JCI insight, 2025. PMID 40059824. doi:10.1172/jci.insight.181443
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA